Form 4: Tandem Diabetes Exec Converts RSUs, Adjusts Holdings

Susan Morrison, EVP & Chief Admin. Officer at Tandem Diabetes Care, converted restricted stock units into common stock and had shares withheld for tax obligations.

Summary

• Susan Morrison, Executive Vice President & Chief Administrative Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions involving the conversion of Restricted Stock Units (RSUs) into common stock.
• On November 17, 2025, Morrison acquired a total of 2,599 shares of common stock through the conversion of RSUs, with an exercise price of $0 per share.
• Concurrently, 744 shares of common stock were disposed of at a price of $18.61 per share to satisfy tax withholding requirements related to the RSU vesting.
• Following these transactions, Morrison's direct beneficial ownership of Tandem Diabetes Care common stock stands at 40,917 shares.
• Morrison also holds 9,587 unvested Restricted Stock Units (3,006 from a May 2023 award and 6,581 from a May 2024 award).

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax withholding). These events are neutral in nature and do not indicate any significant positive or negative developments for the company.

Positives

• The conversion of Restricted Stock Units into common stock indicates the vesting of executive compensation, aligning management's interests with shareholders.
• The executive's continued beneficial ownership of 40,917 shares of common stock demonstrates ongoing commitment to the company.

Negatives

• A portion of the vested shares (744 shares) was disposed of to cover tax obligations, which is a routine event and not a discretionary sale by the executive.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This routine insider transaction, involving the vesting of Restricted Stock Units and subsequent tax withholding, is a standard component of executive compensation in publicly traded companies across various industries, including medical device and healthcare technology sectors. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not directly impact the company's operational performance or financial health. It reflects the executive's continued equity stake.
• Employees: No direct impact on employees beyond the reporting executive.

Next Steps

• The remaining unvested Restricted Stock Units will continue to vest according to their respective schedules, with the 2023 award vesting in eight equal quarterly installments after May 15, 2024, and the 2024 award vesting in eight equal quarterly installments after May 15, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions involving the vesting of Restricted Stock Units and subsequent tax withholding. Such events are standard components of executive compensation and do not provide new material information that would warrant a change in investment recommendation. The executive's continued ownership of a significant number of shares is a positive, but the overall impact on the company's fundamentals or outlook is neutral.

Keywords

TNDM, Tandem Diabetes Care, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Stock Ownership